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Background: There is growing evidence of intravenous administration of prescription 
opioids (POs) in several countries. Preparation of POs for injection may leave residues in 
containers and filters used by people who inject drugs and may lead to adverse health 
outcomes if they are injected.   
Methods: This exploratory study used cross-sectional data from the COSMO study, a 
prospective cohort of out-of-treatment cocaine users carried out in Montréal (Canada) 
between October 2010 and August 2015. For this analysis, only one visit per participant 
was selected, that is, the first time the participant reported PO injection during the 
study.The outcome of interest, “injection of PO residues”, was defined as having injected 
PO residues from a filter and/or a container in the last month. Correlates of this outcome 
were identified using logistic regression analyses. 
Results: Of the 122 participants who reported PO injection during the study period, 
41.8% had injected PO residues. Reporting an unstable source of income (AOR=4.26; 
95% CI: 1.03-17.69), a recent overdose (AOR=5.45; 95% CI: 1.50-19.88) and a 
preponderant use of opiates (mostly opiate use versus other drugs excluding alcohol and 
cannabis) (AOR=2.46; 95% CI: 1.08-5.63) increased the risk of PO residue injection. The 
odds of reporting PO residue injection rose by 7% per unit increase in the score of 
psychological distress (AOR=1.07 per unit increase; 95% CI: 1.01-1.12). 
Conclusions: The findings of this study suggest that PO residue injection is associated 
with markers of vulnerability. Further investigation is needed in order to better 
understand this understudied drug injection practice. 
 








Amidst the significant increase of prescription opioid (PO) misuse in recent years, there is 
growing evidence of intravenous PO administration in several countries. Reports of PO 
injection have risen worldwide, including in the United States (Davis and Johnson, 2008; 
Young et al., 2010; Surrat et al., 2011; Lankenau et al., 2012; Black et al., 2013; Mateu-
Gelabert et al., 2015), Europe (Partanen et al., 2009; Keijzer and Imbert., 2011; Roux et 
al., 2011), South Asia (Larance et al., 2011) and Australia (Degenhardt et al., 2006). In 
Canada, over the past decade, PO injection has gained in popularity among drug users 
across the country (UHRI, 2013; Leclerc et al., 2013; Firestone and Fischer, 2008; Roy et 
al., 2011; Roy et al., 2013; Bruneau et al., 2012; Fischer et al., 2006; PHAC, 2014). Data 
from I-Track, a multisite surveillance system that monitors HIV and hepatitis C virus 
(HCV) infection rates and associated risk behaviors among persons who inject drugs 
(PWID) in Canada, revealed that hydromorphone, morphine and oxycodone, either in tablet 
or capsule form, were injected more often than heroin. These prescription drugs were 
respectively the second, third and fourth most commonly reported injection drugs used in 
the last six months (PHAC, 2014). Only cocaine surpassed them as it was the most reported 
injected drug. 
While PO injection has been observed in several parts of the world, its specific injection 
practices are not well documented. Now, it is generally acknowledged that injection 
practices may vary depending on the types of substances injected, resulting in more or less 
serious consequences for the health of users (Gordon and Lowy, 2005). The ethnographic 
work we carried out in downtown Montréal has allowed us to examine the injection 
techniques used by PWID to prepare PO tablets or capsules that are designed for oral use 
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(Roy et al., 2011). The study findings showed that, due to the physical composition of the 
two most available forms of POs in the area (Dilaudid® and Hydromorph Contin®), 
dissolution was complex and required large amounts of water. This constrained many PO 
injectors to inject themselves repeatedly during a single injection episode, generally using 
the same material several times. Also, as opposed to powder cocaine and the white/beige 
powder heroin available in Montréal, which are easily dissolvable, these PO formulations 
tended to leave significant amounts of residue in the containers and filters used for 
injection. The containers and filters were often kept for further use, a practice referred to 
by users as “doing a wash”, as it implies rinsing the used equipment with water to extract 
the drug residues for injection. Washes were often shared among users who considered 
them valuable goods they could exchange or offer to other users (Roy et al., 2011).  
Injection of drug residues has been previously described among heroin users in the western 
United States, where black tar was the most prevalent form of heroin (Bourgois, 1998; 
Koester et al., 2005; Bourgois and Schonberg, 2009). Ethnographers observed that similar 
to some PO formulations, black tar heroin was not easily dissolvable and left significant 
amounts of residues in filters used for injection. Overall, ethnographic studies highlighted 
the vulnerability of PWID who inject residues, showing that this behaviour was mainly 
practiced by individuals who had unsuccessful income-generating strategies and, 
consequently had to rely on their own or others’ drug residues to relieve opioid withdrawal 
symptoms (Bourgois, 1998; Bourgois and Schonberg, 2009; Roy et al., 2011).  
Drug residue injection entails several serious medical complications including bacterial 
and fungal infections due to re-use of injection equipment (Gordon and Lowy, 2005; Hope 
et al., 2008; Kaushik et al., 2011). With respect to PO specifically, residue injection could 
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increase the risk of injecting insoluble particles found in pharmaceutical tablets or capsules 
destined for oral use. Injection of such particles can cause serious health consequences such 
as pulmonary emboli and ischaemic necrosis (Ng et al., 2015; Roberts, 2002). Finally, drug 
residue injection can be problematic due to the risks of HCV transmission when drug 
residues are shared with other users (Roy et al., 2012). It should be noted that PO residue 
injection was stated as a possible hypothesis explaining the association between PO 
injection and HCV transmission in a cohort study of PWID in Montréal (Bruneau et al., 
2012). Thus, from a public health perspective, there is a need to document this injection 
practice and characterize residue injectors in order to better inform harm reduction 
strategies.  
To date, only four studies have looked at the prevalence of drug residue injection, focusing 
on injecting someone else’s drug residue (Koester et al., 2005; Evans et al., 2009; Roy et 
al., 2012; Le Marchand et al., 2013). To our knowledge, PO residue injection has never 
been measured or discussed explicitly in epidemiological studies. Yet, in addition to our 
ethnographic study, PO drug residue injection has been recently qualitatively reported in 
New York (Mateu-Gelabert et al., 2015), which suggests PO residue injection is not an 
isolated phenomenon.  
The goal of this exploratory study was to estimate the prevalence and correlates of injection 
of PO residue (either one’s own or someone else’s) among PO injectors. Secondary 
analyses were carried out using data from a prospective cohort study on mental health, drug 
use and HIV/HCV among out-of-treatment (OOT) cocaine users. Informed by 
ethnographic studies suggesting higher degrees of social and health vulnerabilities among 
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residue injectors, we examined the relationship between PO residue injection and socio-
demographic characteristics, psychological states and drug use patterns. 
2. Material and methods 
2.1 The COSMO study 
The COSMO study is a prospective cohort study conducted among OOT cocaine users in 
Montréal, Canada, between October 2010 and August 2015 among OOT cocaine users. 
The methodology was described in detail elsewhere (Lévesque et al., 2014). Briefly, to be 
eligible for the COSMO study, participants had to have used cocaine in the last month, 
either by smoking crack or by injection. They also had to speak French or English, be able 
to provide informed consent and be at least 14 years old. Study participants were mainly 
recruited in community-based programs located in downtown Montréal. After providing 
informed consent and contact information, participants completed interviewer-
administered questionnaires at baseline and during five consecutive follow-up visits, 
scheduled at three-month intervals. Detailed contact information was updated at each 
interview and thorough follow-up procedures were used. Participants were paid $30 
financial compensation for their time, at each interview. This research was approved by the 
ethical boards of the Faculty of Medicine and Health Sciences at Université de Sherbrooke 
and of Centre Hospitalier de l’Université de Montréal.  
2.2 Study sample 
The sample included in this analysis was drawn from the COSMO study. Questions about 
injection of PO residues among participants reporting PO injection in the month prior to 
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interviews were added to the baseline and follow-up questionnaires on May 1, 2012. 
COSMO participants who completed questionnaires at that date or thereafter during the 
study period were eligible for this analysis if they had injected PO in the month prior to 
interview. For this paper, only one visit per participant was selected, that is, the first time 
the participant answered yes to the question about PO injection during the study.  
2.3 Measurements 
The outcome of interest for this study was “injection of PO residues,” which was defined 
as having ever injected PO residues from a filter and/or a container in the last month. This 
included one’s own material and material already used by someone else. Based on the 
literature, correlates of injection of PO residues examined include age (younger than 25 
years old vs. older), sex, ethnicity (born in Canada vs. outside), level of education (less 
than high school vs. higher level), unstable housing (defined as having lived or slept at least 
once in a shelter or in any place not intended for housing in the past 3 months), reporting a 
marginal or criminal source of income in the past 3 months (e.g. panhandling, theft, drug 
dealing), sex work (defined as having vaginal, oral or anal sexual relations with a client in 
the past month) and recent drug overdose (past 3 months). The preponderant use of opiates, 
defined as having POs or heroin as the most commonly used drug in the previous month as 
opposed to any other drug excluding alcohol and cannabis, was also assessed as a surrogate 
marker of opiate dependency. Additional information was collected to describe patterns of 
PO injection in the past month, including number of days of injection in a typical week, 
number of injections during a day and main PO injected. Finally, psychological distress, 
assessed using the K10 scale (Kessler, 2002), was used as a continuous variable. K10 
consists of ten questions on non-specific psychological distress and measures the level of 
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anxiety and depressive symptoms a person may have experienced in the previous four-
week period, the final score ranging between 10 and 50.  
2.4 Analyses  
Descriptive statistics including means, medians, standard deviations and interquartile 
ranges (IQR) for continuous variables and frequency distributions for categorical variables 
were used to characterize the study population. Logistic regression analyses were 
conducted to determine the correlates of PO residue injection among PO injectors. All 
variables with p-values <0.05 in bivariate analyses were included in the multivariate model. 
Following the purposeful selection procedure, significant variables with p-values <0.05 
and those with confounding effects were kept in the final model. A variable was considered 
confounding if its removal from the model changed a significant coefficient by more than 
20%. The advantage of the purposeful selection method comes when the analyst is 
interested in risk factor modeling and not just mere prediction (Bursac et al., 2008). The 
algorithm is used in such a way that, in addition to significant covariates, it retains 
important confounding variables, resulting in a possibly slightly richer model. Simulation 
studies demonstrate that the purposeful selection algorithm identifies and retains 
confounders correctly at a larger rate than other selection procedures. Adjusted odds ratios 
(AOR) and 95% confidence intervals (CI) were derived from the final models. SAS 9.3 
software was used to perform the analysis. 
3. Results 
A total of 605 cocaine users were recruited in the COSMO study. Of the 491 cocaine users 
who completed at least one interview between May 1, 2012 and the end of the study, 122 
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participants reported injecting POs in the previous month at least once during the study 
period, and were therefore eligible for this analysis; the majority (101) did so at their first 
interview. Demographic characteristics and patterns of PO injection are shown in Table 1. 
Most of the 122 participants were male (82.8%) and mean age was 37.0 years. In the last 
month, more than half of participants consumed opiates (54.1%), namely Dilaudid® or 
Hydromorph Contin® (41.8%) and heroin (12.3%) as their preponderant drug, followed by 
cocaine, crack or freebase (38.5%). Less than a tenth of participants had another 
preponderant drug such as amphetamines, psychotherapeutics drugs or solvent. Concerning 
PO injection, Dilaudid® was the main PO injected (65.6%) followed by Hydromorph 
Contin® (29.5%), and approximately two-thirds of participants injected at least once a 
week. Multiple injections in a given injection day was common, with slightly more than a 
third of participants injecting at least 4 times a day. 
About four out of ten participants (41.8%) injected PO residues. Ten factors were examined 
as correlates of injection of PO residues in bivariate analyses, namely age, sex, ethnicity, 
level of education, housing, income, sex work, overdose, preponderant use of opiates and 
psychological distress. Results showed that PO injectors who reported injecting PO 
residues were significantly more likely (p<0.05) to be under 25 years old, to report unstable 
housing, marginal or criminal sources of income, recent drug overdose and preponderant 
use of opiates (Table 2). Psychological distress was also positively and significantly 
(p<0.05) associated with residue injection whereas sex, ethnicity, level of education and 
sex work were not. The six factors with p-values <0.05 in bivariate analyses were then 
included in the multivariate analysis and four were retained in the final model (Table 3). 
Participants who had marginal or criminal sources of income (AOR=4.26; 95% CI: 1.03-
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17.69), recent drug overdoses (AOR=5.45; 95% CI: 1.50-19.88) or consumed opiates as 
their preponderant drug (AOR=2.46; 95% CI: 1.08-5.63) were more likely to inject PO 
residues compared to those who did not. The odds of reporting PO residue injection rose 
by 7% per unit increase in the psychological distress score (AOR=1.07 per unit increase; 
95% CI: 1.01-1.12). Despite the fact that age and unstable housing were initially included 
in multivariate analysis, they did not remained significantly associated with PO residues 
injection when controlling for other factors aforementioned. Furthermore, giving that they 
did not constitute confounding factors, they were removed from final multivariate model 
presented in Table 3, following the purposeful selection procedure. 
 
4. Discussion 
To our knowledge, this is the first study to assess the prevalence of PO residue injection 
and identify its correlates among PWID. Our results indicate that 41.8% of study 
participants had injected PO residues between May 2012 and August 2015. While no 
point of comparison exists in the literature, this proportion seems high and is of major 
concern given the potential adverse health outcomes resulting from this practice. Another 
important finding is that this injection practice is associated with markers of vulnerability 
and specific drug use patterns. One marker is income, for which PO residue injectors had 
greater odds of reporting marginal or criminal activity (such as drug dealing, sex work, 
panhandling) as their main source of income. This result is consistent with other studies 
that showed significant associations between illegal or marginal income sources and 
injection risk behaviours or risky patterns of drug use (Richardson et al., 2010; DeBeck et 
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al., 2007; 2011). For instance, in Vancouver, such sources of income have been linked to 
daily heroin injection (Richardson et al., 2010; Debeck et al., 2007; 2011), injecting in 
public places (Richardson et al., 2010; DeBeck et al., 2011), binge drug use and syringe 
sharing (DeBeck et al., 2011). For drug residue injection, it can be hypothesized that, 
compared to legal income sources, marginal or criminal sources of income likely produce 
more irregular or weak income streams, which could force PO injectors to fall back on 
PO residues. These results are consistent with prior ethnographic studies reporting that 
residue injection is mainly practiced by PWID with low-income sources or unsuccessful 
income-generating strategies (Bourgois, 1998; Bourgois and Schonberg, 2009; Roy et al., 
2011).  
PO residue injectors in this study were more likely to report preponderant use of opioid 
substances (heroin or POs) during the last month. In a study sample of PO injectors, this 
association may indicate that individuals who inject residues have more severe opioid 
dependency than other PO injectors. More severe dependency among these PO injectors 
may explain why they inject drug residues to stave off “dopesickness,” particularly when 
financial resources are scarce (Bourgois, 1998; Bourgois and Schonberg, 2009; Roy et 
al., 2011). 
The observation that PO residue injectors were more likely to have overdosed than other 
participants suggests that they not only have more severe opioid dependency but also 
have more intense drug use patterns (Darke et al., 2014).  In our sample, overdoses may 
have been caused by the use of several drugs, and not only opioids, since study 
participants were polysubstance users (minimally cocaine and POs). It is possible that the 
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occurrence of overdoses is a marker of high-risk intensive drug use involving high doses 
and/or hazardous mixtures of substances.   
Finally, our results show that PO injectors who injected residues were more likely to 
suffer from psychological distress as measured by the K10.  Several studies have shown 
that symptoms of anxiety or depression were associated with drug-equipment sharing 
behaviours among drug users (Lundgren et al., 2005; Golub et al., 2007; Reyes et al., 
2007; Lemstra et al., 2011; German et al., 2012; Armstrong et al., 2013).  The 
mechanisms underlying these relationships are not well understood. A possible 
explanation for our findings regarding drug residue injection is that PWID do it as a last 
resort because they are suffering from withdrawal symptoms and have no heroin or other 
opioids on hand. It has been shown that opioid withdrawal can produce symptoms of 
anxiety that can heighten levels of distress (American Psychiatric Association, 2013; 
West and Gossop, 1994). It is also plausible that the experience of suffering from 
withdrawal symptoms and craving, while feeling forced to relieve these symptoms with 
what is perceived as a suboptimal alternative to a full dose of opiate, is altogether 
sufficient to induce a significant rise in level of psychological distress. 
Our study is subject to a number of limitations, the first being that this is an exploratory 
study based on a cross-sectional design. Therefore it is impossible to establish a causal 
link between the studied covariates and PO residue injection. Also, since the study was 
based on secondary analyses of the COSMO study, only people who used cocaine in the 
last month were eligible, thus excluding PO users who did not simultaneously use 
cocaine. While this might have biased the proportion of study participants who had 
injected PO residues, it is impossible to know whether that bias pointed to over- or under-
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estimation of prevalence. Furthermore, similar to most studies involving illicit drug-using 
populations, participants were not randomly recruited, thereby limiting the 
generalizability of our findings. Finally, data for this study were collected through self-
report, which could have led to recall and social desirability biases. However, the impact 
of such biases was possibly limited by the short referral period, and the open and non-
judgmental attitudes of the highly experienced study interviewers. Also, it has been 
shown that self-reported data collected from drug-using populations is generally reliable 
and valid (Darke, 1998). 
 
5. Conclusion 
In light of these findings, development of interventions seems imperative to reduce PO 
residue injection and risk vulnerabilities among PWID in general. Our results highlight 
the need for better access to low-threshold opioid substitution treatment, which should be 
facilitated and maximized among PO injectors. This type of treatment has the potential to 
reduce opioid dependency to more manageable levels which, in turn, could reduce risky 
behaviors (Mateu-Gelabert et al., 2010). Pharmacological approaches should be 
complemented by mental health interventions to reduce distress on emotional, cognitive 
and physiological levels. Furthermore, it is imperative that injection paraphernalia 
distributed in harm reduction programs be revised to allow safer injection practices 
among PWID who inject “new” substances. In this regard, it should be noted that public 
health authorities in Québec have conducted studies to evaluate PO preparation 
techniques and new drug injection equipment that could produce less drug residue (Noël 
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et al., 2015; Leclerc et al., 2015). Prevention messages should also be tailored to inform 
PWID about the risks of drug residue injection and the methods to inject PO more safely.   
In conclusion, residue injection has remained an understudied topic; it has rarely been 
measured or discussed explicitly in epidemiological studies. Thus it is important to 
conduct additional studies examining not only its prevalence and correlates, but also the 
socio-sanitary consequences associated with this injection practice. Such studies could 





Table 1: Demographic characteristics and patterns of PO injection among study 
participants (n=122) 
Characteristics of study participants N (%) 
Age 37.0 (10.2)† 
Sex  
 Male 101 (82.8) 
 Female 21 (17.2) 
Ethnicity  
 Born in Canada 118 (96.7) 
 Born outside Canada 4 (3.3) 
Level of education  
 Less than high school 61 (50.0) 
 Higher than high school 61 (50.0) 
Housing**  
 Stable housing 33 (27.1) 
 Unstable housing 89 (73.0) 
Source of income**  
 Conventional 18 (14.8) 
 Marginal or criminal 104 (85.3) 
Sex work*  
 Yes 17 (13.9) 
 No 105 (86.1) 
Overdose**  
 No 107 (87.7) 
 Yes 15 (12.3) 
Preponderant use of opiates*  
 Prescription opioid or heroin 66 (54.1) 
 Others 56 (45.9) 
Psychological distress (K10)* 27.2 (8.2)† 
Number of days of PO injection in a typical week*  
 ≤1 day/week 43 (35.3) 
 >1 days/week  79 (64.8) 
Number of PO injections during a day*  
 1-3 times/day 79 (64.8) 
 ≥4 times/day 43 (35.3) 
Main PO injected*  
 Dilaudid® 80 (65.6) 
 Hydromorph Contin® 36 (29.5) 
 Others‡ 6 (4.9) 
†Mean (SD). ‡Fetanol, oxycodone or oxycontin and morphine. 




Table 2: Univariate logistic regression analyses of correlates of PO residue injection 





OR (95% CI) P value 
Age     
 <25 years 5 (33.3) 10 (66.7) 1.00 (reference)  
 ≥25 years  66 (61.7) 41 (38.3) 0.31 (0.10-0.97) 0.045 
Sex     
 Male 58 (57.4) 43 (42.6) 1.00 (reference)  
 Female 13 (61.9) 8 (38.1) 0.83 (0.32-2.18) 0.705 
Ethnicity     
 Born in Canada 68 (57.6) 50 (42.4) 1.00 (reference)  
 Born outside Canada 3 (75.0) 1 (25.0) 0.45 (0.05-4.49) 0.499 
Level of education     
 Less than high school 36 (59.0) 25 (41.0) 1.00 (reference)  
 Higher than high school 35 (57.4) 26 (42.6) 0.93 (0.46-1.92) 0.854 
Housing**     
 Stable housing 25 (75.8) 8 (24.2) 1.00 (reference)  
 Unstable housing 46 (51.7) 43 (48.3) 2.92 (1.19-7.17) 0.019 
Source of income**     
 Conventional 15 (83.3) 3 (16.7) 1.00 (reference)  
 Marginal or criminal 56 (53.9) 48 (46.2) 4.29 (1.17-15.70) 0.028 
Sex work*     
 Yes 11 (64.7) 6 (35.3) 1.00 (reference)  
 No 60 (57.1) 45 (42.9) 1.38 (0.47-4.00) 0.559 
Overdose**     
 No 67 (62.6) 40 (37.4) 1.00 (reference)  
 Yes 4 (26.7) 11 (73.3) 4.61 (1.37-15.44) 0.013 
Preponderant use of opiates*     
 Others 38 (67.9) 18 (32.1) 1.00 (reference)  
 Prescription opioid or heroin  33 (50.0) 33 (50.0) 2.11 (1.01-4.42) 0.048 
Psychological distress (K10)* 25.7 (9.0)† 29.3 (6.5)† 1.06 (1.01-1.11) 0.019 




Table 3: Multivariate logistic regression analyses of correlates of PO residue injection  
 Injection of PO residues* 
AOR (95% CI) P value 
Marginal or criminal source of income** 4.26 (1.03-17.69) 0.046 
Psychological distress (K10)* 1.07 (1.01-1.12) 0.019 
Overdose** 5.45 (1.50-19.88) 0.010 
Preponderant use of prescription opioid or heroin** 2.46 (1.08-5.63) 0.032 
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